Contacts: Jessica Moser (Wal-Mart Stores, Inc.) 501/273-4314 option 1
Susan Toth Jackson (Novo Nordisk) 212/867/0123
People With Diabetes Have New, Low-Cost Option for Insulin
Wal-Mart, Novo Nordisk Introduce Co-Branded Insulin
BENTONVILLE, ARK., August 31, 2000 - As healthcare costs continue to rise, people with diabetes have a new, low-cost option for one of their primary medical needs. Wal-Mart and Novo Nordisk Pharmaceuticals, Inc. today introduced Novolin® human insulins (rDNA) to Wal-Mart's ReliOn® brand of diabetes healthcare products. Now available in all Wal-Mart and SAM'S Club pharmacies nationwide, the products will deliver an exceptional value for people who depend on human insulin for the day-to-day management of diabetes.
"Wal-Mart recognizes the financial burden that can sometimes impact patient compliance to a prescribed therapy," said Frank Segrave, vice president divisional merchandise manager for Wal-Mart Pharmacy. "By expanding the ReliOn® portfolio to include Novolin® human insulin we have combined the strength of two powerful healthcare brands to provide the highest quality product at an affordable price."
Novolin® human insulin will be available under the ReliOn® brand for $16.94 for a 10 mL vial. It is the latest addition to Wal-Mart's growing ReliOn® brand of healthcare products which include ReliOn® Insulin Syringes, ReliOn® Glucose Tablets, ReliOn® Blood Pressure Monitors and ReliOn® Lancets.
"We believe that this alliance will help the millions of Americans who are managing their diabetes to have easier, affordable access to this life-saving drug," said Martin Soeters, president of Novo Nordisk Pharmaceuticals, Inc.
Diabetes is the seventh leading cause of death in the United States. Approximately 16 million Americans have the disease, and approximately 798,000 new cases are diagnosed per year. In terms of health care, diabetes costs the nation more than $90 billion per year.
In addition to its ReliOn® brand of diabetes healthcare products, Wal-Mart will launch an in-store initiative in September to reach out to the one-third of Americans with diabetes who are unaware they have the disease. Wal-Mart's Healthy Living: Diabetes Living campaign will include diabetes risk tests for customers, information for people who may be at risk, and health tips and resources to people with diabetes.
According to the Diabetes Control and Complications Trial study (DCCT), tighter blood glucose control plays a critical role in helping people with diabetes delay or avoid the many complications of the disease, including blindness, kidney failure, strokes and neurological disorders.
Under the ReliOn brand, Novolin® human insulin will be offered in three human insulin formulations: Novolin® R (Regular), Novolin® N (NPH) and Novolin® 70/30 (70% NPH, 30 % Regular).
Consumers are reminded to consult with their physician before making any changes in insulin therapy.
Novo Nordisk Pharmaceuticals, Inc., is a US affiliate of Novo Nordisk A/S the world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore, the company is the world's largest producer of enzymes for industrial use. Headquartered in Denmark, Novo Nordisk employs approximately 15,200 people in 68 countries and markets its products in 179 countries. Its B shares are listed on the stock exchanges in Copenhagen and London. Its ADSs are listed on the New York Stock Exchange under the symbol "NVO." A demerger of Novo Nordisk with the intention to spin off the Enzyme Business into a separately listed company is expected to take place around the turn of the year 2000/2001. For further company information, visit Novo Nordisk on the World Wide Web at http://www.novo.dk or in the US at http://www.novo-nordisk.com.
Wal-Mart Stores, Inc. currently operates nearly 2,600 stores and 466 SAM'S Clubs in the United States and more than 1,000 units internationally, and employs more than 1.1 million associates worldwide. Last year, the company raised and donated more than $163 million to charitable and educational organizations nationwide through the Wal-Mart / SAM'S Club Foundation.
Posted 2 September 2000
Last Updated: Thursday February 27, 2014 19:28:21
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.